No one knows the size of the NASH market

Industry is still using a broad estimate for the NASH population, which has led to very different views on the size of the potential market opportunity.

By Jacob Bell • May 16, 2019

On the path to patients, NASH drugs may hit a payer roadblock

Wall Street estimates and clinical data suggest the earliest NASH drugs could come with limited efficacy but high price tags. Healthcare providers fear that won't sit well with payers.

By Jacob Bell • May 15, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Will a big needle burst the NASH bubble?

With less invasive tests still a few years off, doctors worry liver biopsies will limit access to the initial wave of NASH drugs — if any make it to market. 

By Jacob Bell • May 14, 2019

Gilead donates Truvada for PrEP to CDC, with mixed reactions

While the donation will make the preventive treatment available to uninsured Americans, it doesn't lower the cost for others.

By Andrew Dunn • May 10, 2019

Nearing gene therapy launch, Bluebird cautions a slower start

Zynteglo, Bluebird's experimental therapy for beta-thalassemia, could soon be cleared in Europe. Reworking payment models to adjust will take time.

By Ned Pagliarulo • May 9, 2019

Drugmakers will soon be required to disclose prices in TV ads

Forcing pharma's hand, the Trump administration finalized a proposal requiring list prices in DTC advertising, inviting a possible legal challenge from industry.

By Ned Pagliarulo • May 8, 2019

Catalyst dives as FDA approves rival's rare disease drug

Jacobus Pharmaceutical's Ruzurgi is cleared for a different age range than Catalyst's Firdapse, yet investors appear concerned about off-label use eroding the latter's business. 

By Jacob Bell • May 7, 2019

J&J touts YouTube successes after growing spend on the platform 250%

While drugmaker marketing for pharmaceuticals still relies heavily on TV, J&J has found success with digital advertising for its consumer brands. 

By Peter Adams • May 3, 2019

Alnylam posts strong Onpattro sales as competition heats up

Onpattro's performance in the first quarter beat expectations. But can Alnylam sustain that momentum if Pfizer wins approval for its would-be rival tafamidis?

By Ned Pagliarulo • May 2, 2019

Pfizer prospects for tafamidis market

The rare disease tafamidis treats is underdiagnosed, Pfizer says, so increasing awareness will be essential. Payers, meanwhile, may seek outcomes-based contracts.

By Jonathan Gardner • April 30, 2019

At gene therapy meeting, insurance execs grapple with expected cost

As more gene therapies move closer to market, questions around pricing and reimbursement have taken on greater urgency for regulators, payers and drugmakers.

By Ned Pagliarulo • April 30, 2019

Praluent scores heart label, matching Amgen's rival Repatha

The cholesterol drug from Sanofi and Regeneron is now approved for prevention of cardiovascular events like heart attack or stroke.

By Ned Pagliarulo • April 29, 2019

AbbVie wins hep C contract with Washington state in latest 'Netflix' deal

Louisiana inked a similar agreement last month with a Gilead subsidiary, pioneering a model that aims to boost access while containing drug costs.

By Andrew Dunn • Updated April 26, 2019

Praluent's lower list price isn't yielding better sales yet

Though the Sanofi-Regeneron cholesterol drug took a 60% list price cut in March, stateside sales were down 27% due to "significantly increased rebates."

By Jacob Bell • April 26, 2019

Novartis chief defends cell, gene therapy push

CEO Vas Narasimhan has bet heavily on complex medicines, but the pharma's first quarter earnings show that plan is a work in progress.

By Ned Pagliarulo • April 24, 2019

'Meet PillPack': Amazon rolls out Rx delivery direct marketing

The marketing provides a peek behind the curtain of the famously secretive e-commerce giant, which has edged into healthcare in recent years.

By Rebecca Pifer • April 24, 2019

Competition and donut hole discount takes toll on Xarelto sales

Johnson & Johnson, which sells Xarelto in the U.S., saw first quarter sales for the anticoagulant decline 6% despite pricing and prescription increases.

By Jonathan Gardner • April 23, 2019

Patient centricity: Buzzword or rebirth of the CRO industry?

Now that patient centricity is popularizing, CROs are scrambling to look good for sponsors, investors, and patients.

By Natania Barron, Director Global Marketing • April 23, 2019

Sandoz takes United Therapeutics to court for 'anticompetitive' behavior

The generics arm of Novartis recently launched a copycat version of United's top-seller Remodulin, but says a "secret arrangement" is preventing patients from getting it.

By Jacob Bell • April 18, 2019

$300M loan boosts launch of TherapeuticsMD hot flash pill

Bijuva marketing is beginning thanks to an immediate $200 million cash infusion, with the remainder released on regulatory and sales milestones.

By Jonathan Gardner • April 18, 2019

PhRMA's DTC defense rolls out on airwaves and online

While the Trump administration proceeds with a plan to require list price disclosures in TV ads, drugmakers moved ahead with their own efforts — to varying degrees. 

By Andrew Dunn • April 17, 2019

J&J drugs sales outperform despite generic hit

Kicking off first quarter earnings for the industry, J&J managed to post better-than-expected pharma results despite falling Zytiga sales in the U.S.

By Ned Pagliarulo • April 16, 2019

Its ambitions restrained, Amgen sets modest Evenity price

The bone-building osteoporosis drug will carry a list price of $21,900 for a full course of treatment, a discount to competitors from Eli Lilly and Radius.

By Jonathan Gardner • April 16, 2019

Walking the walk: How pharma companies can deliver patient-centric experiences

Few pharma companies deliver on the promise of patient centricity. Here’s what it takes to be truly patient-centric.

By Hensley Evans • April 16, 2019

'Female Viagra' keeps alcohol black box warning amid FDA dispute with Sprout

The regulator was dissatisfied with the design of a post-marketing study that tested the effects of drinking alcohol while on the Addyi pill.

By Andrew Dunn • April 12, 2019